Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding an increase in shareholdings.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity transaction rather than financial performance metrics.
Material Changes
The filing details a transaction involving Dr. S. Dexter, a connected person of Director Dr. P. J. T. Vallance. On January 4, 2013, 157 Ordinary Shares were acquired at a price of 1,369 pence per share. This increase resulted from the re-investment of the dividend paid to shareholders on January 3, 2013, and the subsequent purchase of shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of a specific insider transaction compliant with Disclosure and Transparency Rule 3.1.4R(1)(c).
Key Facts for Investor Verification
- Transaction Date: January 4, 2013.
- Share Price: 1,369 pence per share.
- Volume: 157 Ordinary Shares acquired.
- Parties Involved: Dr. S. Dexter (Connected Person) and Dr. P. J. T. Vallance (Director).
- Source of Funds: Re-investment of dividend paid on January 3, 2013.